Advertisement
Expression of concern Free access | 10.1172/JCI200302
Find articles by Wang, S. in: PubMed | Google Scholar
Find articles by Liang, K. in: PubMed | Google Scholar
Find articles by Hu, Q. in: PubMed | Google Scholar
Find articles by Li, P. in: PubMed | Google Scholar
Find articles by Song, J. in: PubMed | Google Scholar
Find articles by Yang, Y. in: PubMed | Google Scholar
Find articles by
Yao, J.
in:
PubMed
|
Google Scholar
|
Find articles by Mangala, L. in: PubMed | Google Scholar
Find articles by
Li, C.
in:
PubMed
|
Google Scholar
|
Find articles by Yang, W. in: PubMed | Google Scholar
Find articles by Park, P. in: PubMed | Google Scholar
Find articles by Hawke, D. in: PubMed | Google Scholar
Find articles by
Zhou, J.
in:
PubMed
|
Google Scholar
|
Find articles by Zhou, Y. in: PubMed | Google Scholar
Find articles by Xia, W. in: PubMed | Google Scholar
Find articles by
Hung, M.
in:
PubMed
|
Google Scholar
|
Find articles by Marks, J. in: PubMed | Google Scholar
Find articles by Gallick, G. in: PubMed | Google Scholar
Find articles by Lopez-Berestein, G. in: PubMed | Google Scholar
Find articles by Flores, E. in: PubMed | Google Scholar
Find articles by Sood, A. in: PubMed | Google Scholar
Find articles by Huang, S. in: PubMed | Google Scholar
Find articles by
Yu, D.
in:
PubMed
|
Google Scholar
|
Find articles by Yang, L. in: PubMed | Google Scholar
Find articles by Lin, C. in: PubMed | Google Scholar
Published October 1, 2025 - More info
Conventional therapies for breast cancer brain metastases (BCBMs) have been largely ineffective because of chemoresistance and impermeability of the blood-brain barrier. A comprehensive understanding of the underlying mechanism that allows breast cancer cells to infiltrate the brain is necessary to circumvent treatment resistance of BCBMs. Here, we determined that expression of a long noncoding RNA (lncRNA) that we have named lncRNA associated with BCBM (Lnc-BM) is prognostic of the progression of brain metastasis in breast cancer patients. In preclinical murine models, elevated Lnc-BM expression drove BCBM, while depletion of Lnc-BM with nanoparticle-encapsulated siRNAs effectively treated BCBM. Lnc-BM increased JAK2 kinase activity to mediate oncostatin M– and IL-6–triggered STAT3 phosphorylation. In breast cancer cells, Lnc-BM promoted STAT3-dependent expression of ICAM1 and CCL2, which mediated vascular co-option and recruitment of macrophages in the brain, respectively. Recruited macrophages in turn produced oncostatin M and IL-6, thereby further activating the Lnc-BM/JAK2/STAT3 pathway and enhancing BCBM. Collectively, our results show that Lnc-BM and JAK2 promote BCBMs by mediating communication between breast cancer cells and the brain microenvironment. Moreover, these results suggest targeting Lnc-BM as a potential strategy for fighting this difficult disease.
Shouyu Wang, Ke Liang, Qingsong Hu, Ping Li, Jian Song, Yuedong Yang, Jun Yao, Lingegowda Selanere Mangala, Chunlai Li, Wenhao Yang, Peter K. Park, David H. Hawke, Jianwei Zhou, Yan Zhou, Weiya Xia, Mien-Chie Hung, Jeffrey R. Marks, Gary E. Gallick, Gabriel Lopez-Berestein, Elsa R. Flores, Anil K. Sood, Suyun Huang, Dihua Yu, Liuqing Yang, Chunru Lin
Original citation: J Clin Invest. 2017;127(12):4498-4515. https://doi.org/10.1172/JCI91553
Citation for this expression of concern: J Clin Invest. 2025;135(19):e200302. https://doi.org/10.1172/JCI200302
The Editors are aware of potential image anomalies in Figures 4A, 6D, 11E, and Supplemental Figure 11J. The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.
See the related article at JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.